Peters: “Leadership can be isolating, especially for women”
In a video series produced by the ESMO Women for Oncology, Solange Peters reflects on her career and the leadership challenges she has faced
AI applications in oncology go beyond clinical practice
While many models and tools are designed to support clinical decision-making, AI is already serving cancer research for background tasks, with some potential to educate patients too
An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Novel ways presented to mitigate combination therapy toxicity in EGFR-mutant advanced NSCLC
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Two novel approaches provide new insights into prognostic markers for rare adrenal cancers
Detecting ctDNA and a simple four-component scoring system showed some predictive value, but require prospective validation
Long-term nirogacestat shows sustained benefits in desmoid tumours
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Tumour-agnostic drug development is revolutionising precision oncology
While the field is rapidly evolving, regulatory shifts and greater access to tumour profiling are now needed to realise the full benefits for patients
Talazoparib plus axitinib show some signs of efficacy in heavily pretreated cancers
Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours
Can AI and liquid biopsies take precision oncology to the next level?
According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries